Mehmet BERKÖZ, Özlem KANDEMİR, Nurcan ARAS, Sevim ÇELİK KARAKAŞ, Gülay BÖREKÇİ, Serap YALIN

Kronik Hepatit B ve C Enfeksiyonu ile İnterlökin-2 (-330) Gen Polimorfizmi Arasındaki İlişkinin Araştırılması

Amaç: Hepatit B virüs (HBV) ve hepatit C virüs (HCV) enfeksiyonlarının immunopatogenezinde sitokinler oldukça büyük öneme sahiptirler. Th1 hücreleri tarafından salgılanan interlökin-2 (IL-2) hem immun sistemin aktivasyonunda ve hem de homeostazın düzenlenmesinde önemli rol oynayan, immun sistem üzerinde oldukça geniş spektrumlu etkiye sahip olan bir sitokindir. IL-2 -330 gen polimorfizmi ile hastalık ilişkisinin araştırıldığı çok sayıda çalışmaya rağmen, bu sitokin polimorfizminin HBV ve HCV enfeksiyonlarının immunopatogenezindeki rolünü araştıran oldukça az sayıda çalışma bulunmaktadır. Bu çalışmada kronik hepatit B ve C enfeksiyonu ile IL-2 330 gen polimorfizmi arasındaki ilişkinin belirlenmesi amaçlanmıştır. Yöntem: Çalışmaya kronik hepatit B'li 139 hasta, kronik hepatit C'li 101 hasta ve kontrol grubu olarak 87 sağlıklı birey dahil edilmiştir. Hasta ve kontrol grubundaki bireylerden yaklaşık 2 ml EDTA'lı tüplere kan alınmış ve DNA izolasyon kiti kullanılarak genomik DNA izole edilmiştir. Elde edilen DNA'lardan tek nükleotid polimorfizmi (SNP) polimeraz zincir reaksiyonu-confronting twopair primers (PCR-CTPP) yöntemi ile araştırılmıştır. Bulgular: Hepatit B hasta grubunda IL-2 -330 TT, GT ve GG genotip sıklığı sırasıyla %23.7, %53.2 ve %23; kontrol grubunda ise %27.6, %50.6 ve %21.8 olarak saptanmıştır (p>0.05). Hepatit C hasta grubunda ise; TT, GT ve GG genotip sıklığı %34.7, %56.4 ve %8.9; kontrol grubunda ise %27.6, %50.6 ve %21.8 olarak saptanmış; GG genotip sıklığı kronik hepatit C hastalarında kontrol grubuna göre daha düşük bulunmuştur (p0.05). Kronik hepatit C'li hastalarda ise T allel sıklığı %69.4, kontrol grubunda ise %52.9, G alleli ise hasta grubunda %30.6, kontrol grubunda ise %47.1 olarak belirlenmiştir (p

Investigation of the Association between Chronic Hepatitis B and C Infection and Interleukin 2 (-330) Gene Polymorphism

Objective: Cytokines has an important role in the immunopathogenesis of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Interleukin-2 (IL-2) secreted by Th1 cells which plays an important role in regulating both in activation of the immune system and homeostasis, is a cytokine having a wide spectrum of effects on the immune system. Although there are many studies investigating the relationship between IL-2 -330 gene polymorphism and diseases, a few studied was found to investigate the role in the immunopathogenesis of HBV and HCV infections of this cytokine polymorphisms. This study was aimed to determine the relationship between IL-2 -330 gene polymorphisms and chronic hepatitis B and C infections. Methods: A total of 139 patients with chronic hepatitis B, 101 patients with hepatitis C and 87 healthy subjects as control groups were included into this study. Approximately 2 ml of blood from patients and control groups were taken into tubes containing EDTA, and genomic DNA was isolated using DNA isolation kit. Single nucleotide polypmorphsim from the obtained DNAs was investigated using the polymerase chain reaction-confronting two-pair primers (PCR-CTPP) methods. Results: The genotype frequencies of IL-2 -330 TT, GT, GG were detected as 23.7%, 53.2%, 23% in patients with chronic hepatitis B and 27.6%, 50.6%, 21.8% in control groups, respectively (p>0.05). The frequencies of TT, GT, GG genotypes were found to be 34.7%, 56.4%, 8.9% in patients with chronic hepatitis C and 27.6%, 50.6%, 21.8% in control group, respectively. GG genotype frequency was significantly lower in patient groups with hepatitis C compared with the control group (p0.05). The frequencies of T and G alleles were found to be 69.4%, 30.6% in patients with chronic hepatitis C and 52.9%, 47.1% in control groups, respectively (p

PDF

___

WHO: Draft global health sector strategy on viral hepatitis, 2016-2021-the first of its kind.Erişim adresi: http://www.who.int/hepatitis/strategy2016 /Draft_global_health_sector_strategy_viral_hepatitis_13nov.pdf?ua=1. Erişim tarihi: 13.10.2015.
Kaplan DE. Immunopathogenesis of hepatitis C virus Infection. Gastroenterol Clin North Am 2015;44:735-60.
Saxena R, Kaur J. Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. World J Hepatol. 2015:18;7:1572-80.
Smith AJP, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 2009;20:43-59.
Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, Wang SY, Tong LX. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 2009;15:5610-9.
Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine & Growth Factor Reviews. 2006;17:349-66.
Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28:109-23.
Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003;74:961-5.
Nelson BH. IL-2, Regulatory T Cells, and Tolerance. The Journal of Immunology. 2004;172:3983-8.
Ballesteros-Tato A. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases. Immunotherapy. 2014;6:1207-20.
Baykal Y, Karaayvaz M, Kutlu M. Interleukins. T Klin J Med Sci 1998;18:77-84.
Interleukin-2. Cytokines and cells. Erişim adresi: http://www.copewithcytokines.de/cope.cgi?key=IL2. Erişim tarihi:07.02.2016.
Polat B, Halıcı Z. Sitokin İmmün Modülatörler, İnterferonlar, İnterlökin-2. Turkiye Klinikleri J Hem Onc-Special Topics. 2012;5:44-51.
Abbas AK, Lohr J, Knoechel B, Nagabhushanam V. T cell tolerance and autoimmunity. Autoimmun Rev. 2004;3:471-5.
Abbas AK, Katzman S, Villarino A, Hoyer K, Dooms H. Tolerance, Autoimmunity and Immune-Mediated Inflammatory Diseases. http://www.turkimmunoloji.org.tr/2009_immunoloji_kongre/immunoloji_ko ngresi_2009_bildiri_ozetleri.pdf 17.01.2016.
Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci USA. 1997;94:3168-71.
Schmidt J, Blum HE, Thimme R. T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect. 2013;2:e15.
Kasprzak A, Zabel M, Biczysko W, Wysocki J, Adamek A, Spachacz R, Surdyk Zasada J. Expression of cytokines (TNF-alpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. J Histochem Cytochem. 2004;52:29-38.
McCaughan GW, Gorrell MD, Bishop GA, Abbott CA, Shackel NA, McGuinness PH, Levy MT, Sharland AF, Bowen DG, Yu D, Slaitini L, Church WB, Napoli J. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev. 2000;174:172-91.
Barış S, Akyürek Ö, Dursun A, Akyol M.The impact of the IL-1?, IL-1Ra, IL-2, IL and IL-10 gene polymorphisms on the development of Behcet's disease and their association with the phenotype. Med Clin (Barc). 2016 May 6;146:379- 83.
Zhao H, Wang R. IL-2 -330T/G polymorphism and cancer risk: a meta-analysis. Onco Targets Ther. 2015;8:1753-60.
Sobjanek M, Zablotna M, Bien E, Glen J, Sokolowska-Wojdylo M, Ruckemann Dziurdzinska K, Nowicki R. Clinical significance of IL-2 and IL-10 gene polymorphisms and serum levels in patients with basal-cell carcinoma. Biomark Med. 2016;10:185-95.
Gao QJ, Liu DW, Zhang SY, Wu LH, Jia M. Relations between IL-2 -330 polymorphisms and the outcome of hepatitis B and/or hepatitis C virus infection. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31:1041-5.
Wu JF, Hsu HY, Chiu YC, Chen HL, Ni YH, Chang MH. The effects of cytokines on surface spontaneous hepatitis B antigen seroconversion in chronic hepatitis B virus infection. J Immunol. 2015;194:690-6.
Zhao H, Wang R. IL-2 -330T/G polymorphism and cancer risk: a meta-analysis. Onco Targets Ther. 2015;8:1753-60.
Wei YS, Lan Y, Zhang L, Wang JC. Association of the interleukin-2 polymorphisms with interleukin-2 serum levels and risk of nasopharyngeal carcinoma. DNA Cell Biol. 2010;29:363-8.
Liang C, DU W, Dong Q, Liu X, Li W, Wang Y, Gao G. Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves' disease. Exp Ther Med. 2015;9:925-30.
Sayad A. The association of -330 interleukin-2 gene polymorphism and HLA DR15 allele in Iranian patients with multiple sclerosis. Int J Immunogenet. 2014;41:330-4.
Yücel A, Dilek K, Saba D, Ozçimen AA, Yurtkuran M, Oral HB. Interleukin-2 gene polymorphism in Turkish patients with Behçet's disease and its association with ocular involvement. Int J Immunogenet. 2013;40:349-55.
Queiroz DM, Saraiva IE, Rocha GA, Rocha AM, Gomes LI, Melo FF, Bittencourt PF. IL2 -330G polymorphic allele is associated with decreased risk of Helicobacter pylori infection in adulthood. Microbes Infect. 2009;11:980-7.
Nasi M, Riva A, Borghi V, D'Amico R, Del Giovane C, Casoli C, Galli M, Vicenzi E, Gibellini L, De Biasi S, Clerici M, Mussini C, Cossarizza A, Pinti M. Novel genetic association of TNF-?-238 and PDCD1-7209 polymorphisms with long- term non-progressive HIV-1 infection. Int J Infect Dis. 2013;17:e845-50.
Yilmaz V, Demirbilek V, Gürses C, Yentür SP, Uysal S, Yapici Z, Yilmaz G, Muncey A, Cokar O, Onal E, Gökyiğit A, Saruhan-Direskeneli G. Interleukin (IL)-12, IL-2, interferon-gamma gene polymorphisms in subacute sclerosing panencephalitis patients. J Neurovirol. 2007;13:410-5.
Bei CH, Bai H, Yu HP, Yang Y, Liang QQ, Deng YY, Tan SK, Qiu XQ. Combined effects of six cytokine gene polymorphisms and SNP-SNP interactions on hepatocellular carcinoma risk in Southern Guangxi, China. Asian Pac J Cancer Prev. 2014;15:6961-7.
Saxena R, Chawla YK, Verma I, Kaur J. Effect of IL-12B, IL-2, TGF-?1, and IL-4 polymorphism and expression on hepatitis B progression. J Interferon Cytokine Res. 2014;34:117-28.